

***Fiscal Year 2024 Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Transforming Diagnosis Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRARPTrDA</p>	<p>Single Principal Investigator (PI) Option: Independent investigators at all career levels (or equivalent).</p> <p>Career Initiation or Transition Partnering PI Option (CIT):</p> <ul style="list-style-type: none"> • Initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 years within their first independent research position • Transition investigators may be at any level, but new to either the Alzheimer’s disease/Alzheimer’s disease-related dementias (AD/ADRD) and/or traumatic brain injury (TBI) fields 	<ul style="list-style-type: none"> • Supports research seeking to transform diagnosis and prognosis to better determine the trajectory, long-term outcomes, and impact of AD/ADRD following military service and/or TBI. • <i>Studies are required to prospectively recruit study participants.</i> • Clinical trials are NOT allowed; data and/or human anatomical substances from an existing clinical trial may be used. • Community collaboration is required. • Animal studies are <i>not</i> allowed. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> • CIT is available. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0 million (M) for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 22, 2024 5:00 p.m. Eastern time</p> <p>Application: June 20, 2024 11:59 p.m. Eastern time</p>
<p>Transforming Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRARPTrRA</p>	<p>Single PI Option: Independent investigators at all career levels (or equivalent).</p> <p>CIT:</p> <ul style="list-style-type: none"> • Initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 years within their first independent research position • Transition investigators may be at any level, but new to either the AD/ADRD and/or TBI fields 	<ul style="list-style-type: none"> • Supports transformative research studies that reduce risk of or prevent the development of AD/ADRD with near-term, high-impact outcomes and demonstrate significant positive impact toward improving patient care and/or quality of life. Risk reduction considering TBI is of particular interest. • Clinical trials are NOT allowed. • Preliminary data are required. • Community collaboration is required for projects involving clinical research. • Studies with prospective human subjects’ enrollment are allowed. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> • CIT is available. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.0M for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): May 22, 2024 5:00 p.m. Eastern time</p> <p>Application: June 20, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Transforming Care Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRARPTrCA</p>	<p>Single PI Option: Independent investigators at all career levels (or equivalent).</p> <p>CIT:</p> <ul style="list-style-type: none"> • Initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 years within their first independent research position • Transition investigators may be at any level, but new to either the AD/ADRD and/or TBI fields 	<ul style="list-style-type: none"> • Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both that clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not include medical care (such as medical interventions administered by a physician). • Clinical trials ARE allowed. • Preliminary data are required. • Community collaboration is required. • Animal studies are <i>not</i> allowed. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> • CIT is available. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is: <ul style="list-style-type: none"> ○ \$1.4M in total costs for the base option ○ \$1.6M in total costs for the CIT • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 22, 2024 5:00 p.m. Eastern time</p> <p>Application: June 20, 2024 11:59 p.m. Eastern time</p>